Suicidal Behavior and Depression in Smoking Cessation Treatments
Open Access
- 2 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27016
Abstract
Two treatments for smoking cessation—varenicline and bupropion—carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increased risk in smoking or smoking cessation independent of treatment, and differences between drugs are unknown. From the FDA's Adverse Event Reporting System (AERS) database from 1998 through September 2010 we selected domestic, serious case reports for varenicline (n = 9,575), bupropion for smoking cessation (n = 1,751), and nicotine replacement products (n = 1,917). A composite endpoint of suicidal/self-injurious behavior or depression was defined as a case with one or more Preferred Terms in Standardized MedDRA Query (SMQ) for those adverse effects. The main outcome measure was the ratio of reported suicide/self-injury or depression cases for each drug compared to all other serious events for that drug. Overall we identified 3,249 reported cases of suicidal/self-injurious behavior or depression, 2,925 (90%) for varenicline, 229 (7%) for bupropion, and 95 (3%) for nicotine replacement. Compared to nicotine replacement, the disproportionality results (OR (95% CI)) were varenicline 8.4 (6.8–10.4), and bupropion 2.9 (2.3–3.7). The disproportionality persisted after excluding reports indicating concomitant therapy with any of 58 drugs with suicidal behavior warnings or precautions in the prescribing information. An additional antibiotic comparison group showed that adverse event reports of suicidal/self-injurious behavior or depression were otherwise rare in a healthy population receiving short-term drug treatment. Varenicline shows a substantial, statistically significant increased risk of reported depression and suicidal/self-injurious behavior. Bupropion for smoking cessation had smaller increased risks. The findings for varenicline, combined with other problems with its safety profile, render it unsuitable for first-line use in smoking cessation.Keywords
This publication has 24 references indexed in Scilit:
- Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance DatabaseEuropean Journal of Clinical Pharmacology, 2011
- Smoking and Suicidal Behaviors in the National Comorbidity Survey: ReplicationJournal of Nervous & Mental Disease, 2007
- Depression during tobacco abstinenceNicotine & Tobacco Research, 2007
- Effects of abstinence from tobacco: Valid symptoms and time courseNicotine & Tobacco Research, 2007
- Suicidal Adverse Events in Pediatric Randomized, Controlled Clinical Trials of Antidepressant Drugs Are Associated with Active Drug Treatment: AMeta-AnalysisJournal of Child and Adolescent Psychopharmacology, 2006
- Smoking and the Risk of Suicidal BehaviorArchives of General Psychiatry, 2005
- Nicotine replacement therapy for smoking cessation2004
- Cigarette Smoking and Suicide: A Prospective Study of 300, 000 Male Active-duty Army SoldiersAmerican Journal of Epidemiology, 2000
- A Meta-Analysis to Assess the Incidence of Adverse Effects Associated with the Transdermal Nicotine PatchDrug Safety, 1998
- Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reductionPsychopharmacology, 1988